Time to Stop Giving Toxic Drugs to Transplant Patients?

Highlights•Kidney transplant patients can minimize or avoid using certain anti-rejection drugs that have serious side effects•Physicians can substitute other drugs that are less toxic•The strategy may benefit the more than 16,000 U.S. patients who receive kidney transplants each year; preventing rejection requires a life-long delicate balance of medication

Newswise — Washington, DC (September 22, 2011) — Patients who receive kidney transplants must take lifelong medications that, while preventing organ rejection, can also compromise other aspects of health. Immunosuppresive drugs called calcineurin inhibitors protect transplanted organs from being rejected, but they can be toxic to the kidneys over the long term and can make patients susceptible to infection, cancer, and other threats.

A new analysis has found that transplant patients can safely minimize or avoid using calcineurin inhibitors. The study, conducted by Richard Borrows, MD and his colleagues at the Renal Institute of Birmingham, in England, appears in an upcoming issue of the Journal of the American Society Nephrology (JASN), a publication of the American Society of Nephrology.

The investigators examined dozens of studies conducted between1966 and 2010 that compared different treatments following kidney transplantation. When they weighed the risks and benefits of avoiding or reducing calcineurin inhibitors immediately after kidney transplantation, the researchers found that the strategy improves kidney function without causing rejection in the short-to-medium period after transplantation. In many cases, patients took newer immunosuppressive drugs that are less toxic to the kidneys.

Approximately 94% of kidney transplant recipients take calcineurin inhibitors after being discharged from the hospital. “This study suggests that after 30 years of using calcineurin inhibitors, it may now be possible to undertake safe and effective transplantation without these drugs, at least in some groups of patients,” said Dr. Borrows.

Study co-authors include Adnan Sharif, MD, Shazia Shabir, MBBS, Sourabh Chand, MBBS, Paul Cockwell, PhD, and Simon Ball, PhD (Renal Institute of Birmingham, in England).

Disclosures: The authors reported no financial disclosures.

The article, entitled “Meta-analysis of Calcineurin Inhibitors in Kidney Transplantation,” will appear online at http://jasn.asnjournals.org/ doi 10.1681/ASN.2010111160

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, and with more than 13,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.